Canada should improve the support its employment services offer to help laid-off workers find a new job more quickly, according to a new OECD report.
Specific country notes have been prepared using data from the database OECD Health Statistics 2015, July 2015 version. The notes are available in PDF format.
A dashboard of key government indicators by country, to help you analyse international comparisons of public sector performance.
In a boost for international efforts to strengthen co-operation against offshore tax evasion, seven new countries have joined the agreement to exchange information automatically under the OECD/G20 standard.
English, PDF, 955kb
This country note provides information on latest trends in income inequalities as well as key findings from the 2015 OECD report "In it Together: Why less inequality benefits all".
Low oil prices and monetary easing are boosting growth in the world’s major economies, but the near-term pace of expansion remains modest, withabnormally low inflation and interest rates pointing to risks of financial instability, according to the OECD’s latest Interim Economic Assessment.
This publication contains statistics on fisheries in OECD member countries (with the exception of Austria, Israel and Slovenia) and some non-member economies (Argentina, Colombia, Latvia, Chinese Taipei, Thailand) from 2006 to 2013. Data provided concern fishing fleet capacity, employment in fisheries, fish landings, aquaculture production, recreational fisheries, government financial transfers, and imports and exports of fish.
English, PDF, 96kb
This country note from Going for Growth 2015 for Canada identifies and assesses progress made on key reforms to boost long-term growth, improve competitiveness and productivity and create jobs.
Canada admitted 257 900 new permanent residents in 2012, equivalent to about 0.7% of the resident population and close to the average since 2006.
English, PDF, 478kb
This country profile describes in details the Canadian pharmaceutical system, including decision-making processes for regulatory approval, reimbursement and pricing; assessment guidelines; institution and stakeholders involved and specific policies for new high cost drugs, when available.